Exploratory analysis of leucine-rich alpha-2-glycoprotein, C-reactive protein, and mucosal gene expression in budesonide-treated patients with ulcerative colitis
Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease in which mucosal healing (MH) is an important therapeutic target. Because repeated endoscopic assessment is burdensome, noninvasive biomarkers such as leucine-rich alpha-2-glycoprotein (LRG) may be useful. This exploratory study examined serum LRG, C-reactive protein (CRP), and mucosal gene expression in patients with UC treated with budesonide 2-mg rectal foam. Methods: Outpatients with mild-to-moderate UC received budesonide 2-mg rectal foam twice daily for 6 weeks. Endoscopic findings, serum LRG and CRP levels, and mucosal gene expression were assessed at Week 0 and Week 6. Paired mucosal samples were available for 8 patients at non-inflamed sites and for 5 patients at inflamed sites. MH at Week 6 was defined as a Mayo endoscopic subscore ≤1, a rectal bleeding subscore of 0, and a stool frequency subscore ≤1. Results: Eight patients were included, and 4 (50.0%) achieved MH at Week 6. Serum LRG decreased in all 8 patients (P = 0.0078). The within-group P value was 0.1250 in both the MH and non-MH groups, and the change in LRG did not differ significantly between the groups (P = 0.2000). At the non-inflamed site, the panel-wide expression score decreased in 7 of 8 patients (P = 0.0547). Expression scores for 5 functional modules decreased in all 8 patients (P = 0.0078; q = 0.0313). At Week 0, 8 genes showed nominally higher expression at inflamed sites in patients without MH, although none remained significant after adjustment across the 249 analyzed genes. No adverse events were reported. Conclusion: Budesonide rectal foam treatment was followed by decreases in serum LRG and broad reductions in mucosal expression across the measured 249-gene panel. The study provided no evidence that the magnitude of the LRG change differed according to MH status. The observed gene-expression differences remain hypothesis-generating and require validation in independent cohorts.
Authors
- Katsutoshi Inagaki (ORCID: https://orcid.org/0009-0009-9170-0494)
- Katsuyoshi Matsuoka (ORCID: https://orcid.org/0000-0002-2950-7660)
- Toshihide Ohmori
- Toshiki Ichimori
- Ken Takeuchi (ORCID: https://orcid.org/0000-0002-5103-5209)
- Takayuki Matsumoto (ORCID: https://orcid.org/0000-0001-9786-3854)
- Tetsuji Naka
Publication Details
- Journal
- Inflammatory Intestinal Diseases
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1159/iid/adeag016
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00